Compare
Protara Therapeutics, Inc. vs Instil Bio, Inc. vs Compass Therapeutics, Inc. vs Metagenomi Therapeutics, Inc.
| Latest fiscal year | Protara Therapeutics, Inc. TARA | Instil Bio, Inc. TIL | Compass Therapeutics, Inc. CMPX | Metagenomi Therapeutics, Inc. MGX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $25.21M |
| Revenue growth (YoY) | n/a | n/a | -100.0% | -51.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -380.9% |
| Net margin | n/a | n/a | n/a | -348.5% |
| Net income | -$57.44M | -$71.37M | -$66.49M | -$87.87M |
| EPS (Diluted) | -$1.34 | -$10.70 | n/a | -$2.36 |
| Operating cash flow | -$56.37M | -$36.62M | -$49.14M | -$88.89M |
| Free cash flow | -$56.46M | n/a | -$49.17M | -$89.47M |
| Cash & equivalents | $49.66M | $6.64M | $30.64M | $41.72M |
| Total assets | $209.47M | $203.52M | $219.59M | $221.10M |
| Total liabilities | $13.06M | $89.66M | $22.80M | $62.51M |
| Shareholders' equity | $196.41M | $113.87M | $196.79M | $158.60M |
| Return on year-end equity | -29.2% | -62.7% | -33.8% | -55.4% |
| Shares outstanding | 53.59M | 6.78M | 178.32M | 37.62M |
Revenue, most recent five fiscal years
| Fiscal year | Protara Therapeutics, Inc. | Instil Bio, Inc. | Compass Therapeutics, Inc. | Metagenomi Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $2.95M Ended 2014-12-31 | $0 Ended 2021-12-31 | $0 Ended 2025-12-31 | $25.21M Ended 2025-12-31 |
| 1 year earlier | n/a | $138.0K Ended 2020-12-31 | $850.0K Ended 2024-12-31 | $52.30M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $44.76M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |